

\$20 Million By 2020 Campaign



Lung Cancer Is The Leading Cause of Cancer Death

Through consistent advocacy efforts, GO₂ Foundation (formerly the Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation) played a vital role in establishing the Lung Cancer Research Program (LCRP) within the Congressionally Directed Medical Research Program administered by the Department of Defense – and works actively every year to increase funding. The LCRP is now the largest lung cancer research program – public or private – outside of the National Cancer Institute at the National Institutes of Health.

The LCRP is actively conducting clinical trials testing new therapies, including immunotherapies and novel types of precision medicines for patients with specific genetic changes in their lung cancer. To continue addressing this gap in research, Congress must restore funding levels back to **\$20 Million by 2020!**

\$141,500,000

Total Appropriations for the LCRP from FY09-FY19

Risk Assessment

Prevention

Early Detection

Treatment

Survivorship & Outcome



CONTACT: Elridge Proctor | Senior Director, Government Affairs & Public Policy | eproctor@go2foundation.org | 202-463-2080

1700 K Street, NW, Suite 660, Washington, DC 20006 | 1100 Industrial Road, #1, San Carlos, CA 94070

go2foundation.org

\$20 Million By 2020 Campaign



Restoration of Full Funding for Lung Cancer Research

First secured in 2008 by GO₂ Foundation (formerly the Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation), the Lung Cancer Research Program (LCRP) was established in FY09 with federal appropriations of \$20 million. It has played a critical role in supporting high-impact, innovative lung cancer research within the military and general public. Congress must restore funding levels back to **\$20 Million by 2020!**


Why Fund a Lung Cancer Research Program?

VISION

Eradicate deaths from lung cancer to better the health and welfare of the military and the American public.

MISSION

Support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.



FY09-FY17 LCRP Investment Portfolio*

*Percentage dollars invested and (number of awards)

Why \$20 Million By 2020 Campaign?

- Lung cancer is the leading cause of cancer deaths in the U.S.
- Military men and women and veterans are at a higher risk for lung cancer than the general public.
- The 5-year survival rate is only 18% despite advancements in current lung cancer treatments.
- LCRP has been underfunded the past 10 years below its original \$20M level, thus limiting research grants.
- To date, lung cancer is underfunded and underrepresented relative to the high rates of lung cancer prevalence, morbidity, and mortality.

Source: *Congressionally Directed Medical Research Programs-Lung Cancer Research Program Highlights, 2019.*

